ReviewCell and tissue research2012
Achieving CNS axon regeneration by manipulating convergent neuro-immune signaling.
Review in Cell and tissue research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Nonresolving Neuroinflammation Regulates Axon Regeneration in Chronic Spinal Cord Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Electroacupuncture Alleviates Pain by Suppressing P2Y12R-Dependent Microglial Activation in Monoarthritic Rats.Neurochemical research · 2024Article
- Non-resolving neuroinflammation regulates axon regeneration in chronic spinal cord injury.bioRxiv : the preprint server for biology · 2024Article
- A system for bioelectronic delivery of treatment directed toward wound healing.Scientific reports · 2023Article
- Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022Review
- Astrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective.Frontiers in immunology · 2022Review
- S100-β aggravates spinal cord injury via activation of M1 macrophage phenotype.Journal of musculoskeletal & neuronal interactions · 2021Article
- Machine intelligence identifies soluble TNFa as a therapeutic target for spinal cord injury.Scientific reports · 2021Article
- Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation.EBioMedicine · 2019Review
- Spinal Cord Injury Scarring and Inflammation: Therapies Targeting Glial and Inflammatory Responses.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury.Brain : a journal of neurology · 2018Article
- Molecular and cellular identification of the immune response in peripheral ganglia following nerve injury.Journal of neuroinflammation · 2018Article
- Neuron-Macrophage Co-cultures to Activate Macrophages Secreting Molecular Factors with Neurite Outgrowth Activity.Journal of visualized experiments : JoVE · 2018Article
- Inflammatory Activation of Microglia and Astrocytes in Manganese Neurotoxicity.Advances in neurobiology · 2017Review
- Improved recovery from spinal cord injury in rats with chronic parvovirus serotype-1a infection.Spinal cord · 2016Article
- CCL2 Mediates Neuron-Macrophage Interactions to Drive Proregenerative Macrophage Activation Following Preconditioning Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes.Journal of neurotrauma · 2015Review
- Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Neuroinflammation triggered by β-glucan/dectin-1 signaling enables CNS axon regeneration.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Gene delivery strategies to promote spinal cord repair.Biomarker insights · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
After central nervous system (CNS) trauma, axons have a low capacity for regeneration. Regeneration failure is associated with a muted regenerative response of the neuron itself, combined with a growth-inhibitory and cytotoxic post-injury environment. After spinal cord injury (SCI), resident and infiltrating immune cells (especially microglia/macrophages) contribute significantly to the growth-refractory milieu near the lesion. By targeting both the regenerative potential of the axon and the cytotoxic phenotype of microglia/macrophages, we may be able to improve CNS repair after SCI. In this review, we discuss molecules shown to impact CNS repair by affecting both immune cells and neurons. Specifically, we provide examples of pattern recognition receptors, integrins, cytokines/chemokines, nuclear receptors and galectins that could improve CNS repair. In many cases, signaling by these molecules is complex and may have contradictory effects on recovery depending on the cell types involved or the model studied. Despite this caveat, deciphering convergent signaling pathways on immune cells (which affect axon growth indirectly) and neurons (direct effects on axon growth) could improve repair and recovery after SCI. Future studies must continue to consider how regenerative therapies targeting neurons impact other cells in the pathological CNS. By identifying molecules that simultaneously improve axon regenerative capacity and drive the protective, growth-promoting phenotype of immune cells, we may discover SCI therapies that act synergistically to improve CNS repair and functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.